Takeda

Presage and Millennium enter cancer research agreement

Monday, April 9, 2012 09:59 AM

Presage Biosciences, a Seattle, Wash.-based company that identifies clinically viable oncology drug combinations, has entered into a cancer research agreement with Millenium, Takeda’s oncology arm based in Cambridge, Mass.

More... »

Takeda joins SGC, funds drug research

Friday, April 6, 2012 11:34 AM

Takeda Pharmaceutical has joined the Structural Genomics Consortium (SGC), based at the Universities of Toronto and Oxford, England, to fund collective drug research aimed at bringing new, more effective medicines to market faster.

More... »

Amgen, AstraZeneca to develop and commercialize inflammation portfolio

Monday, April 2, 2012 04:38 PM

Amgen and AstraZeneca have agreed to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)).

More... »

Takeda establishes development center in China

Friday, February 10, 2012 09:54 AM

Takeda Pharmaceutical has established the Takeda Shanghai Development Center ("TSDC") within the Shanghai-based Takeda (China) Holdings (TCH), a wholly owned subsidiary of Takeda.

More... »

Interim data released on phase I Adcetris trial

Friday, January 27, 2012 02:01 PM

Seattle Genetics and Millennium, the Takeda oncology company, released interim results from 32 patients treated to date in a phase I clinical trial of Adcetris (brentuximab vedotin) administered in combination or sequentially with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma (sALCL) and other CD30-positive mature T-cell lymphoma patients.

More... »

Takeda to cut 2,800 jobs as it absorbs Nycomed

Wednesday, January 18, 2012 12:21 PM

Osaka, Japan-based Takeda Pharmaceutical plans to consolidate its R&D site operations and cut its workforce by 2,800 to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and culture.

More... »

Takeda to integrate two subsidiaries in California

Wednesday, December 21, 2011 01:47 PM

Takeda Pharmaceutical will integrate two wholly-owned subsidiaries, Takeda San Diego (TSD) and Takeda San Francisco (TSF) on January 1, 2012. TSD will become the surviving company and change its name to Takeda California (TCAL) the same day. Keith Wilson, current president of TSD, will become the president of the new company.

More... »

Takeda to acquire Intellikine for $190 million

Wednesday, December 21, 2011 01:31 PM

Takeda Pharmaceutical and Intellikine have entered into an agreement for Takeda America Holdings to acquire Intellikine by cash. Takeda expects that the transaction will be finalized in January 2012. Under the agreement, Takeda America Holdings will acquire Intellikine for $190 million upfront and up to $120 million in additional potential clinical development milestone payments.

More... »

Takeda acquires Nycomed for $13.7 billion

Tuesday, August 2, 2011 12:50 PM

Japanese drug maker Takeda Pharmaceutical secured EU approval for its $13.68 billion acquisition of privately owned Nycomed to reinforce its presence in emerging markets, according to Reuters.

More... »

PPD shares rise on takeover rumors

Monday, July 18, 2011 01:51 PM

Shares of CRO Pharmaceutical Product Development (PPD) rose 16% to levels not touched in more than two-and-a-half years on Monday, a day after a Wall Street Journal report said the company was looking to sell itself, reported Reuters.

More... »